Israel-based healthcare company Dune Medical Devices has completed the first stage of a $21m equity round, raising $14m from investors including sports and manufacturing holding company Kraft Group.
Other investors in the round included medical technology advisory Boston Medtech Advisors, venture capital firm Canepa Advanced Healthcare Fund and private equity company Apax Partners.
Dune previously gained $12.5m from a 2006 series B round and $5m from a 2004 series A, both of which were led by Apax.
Dune’s MarginProbe System enables real-time detection of cancer while surgery is being performed, allowing surgeons to ensure they have removed all cancerous tissue and reducing the need for secondary surgery.
“We are thrilled that the MarginProbe is so well received in the US, and that patients and surgeons are seeing consistently strong results,” said Dan Hashimshony, chief executive of Dune. “This financing will enable us to significantly increase the market’s access to the MarginProbe throughout the US.”